一例神经内分泌癌-acinar腺癌混合瘤：前列腺癌三联疗法的应用。

Q4 Medicine IJU Case Reports Pub Date : 2024-09-01 DOI:10.1002/iju5.12778

Junichi Ikeda, Hisanori Taniguchi, Hiroki Takayama, Yuki Masuo, Takahiro Nakamoto, Katsunori Uchida, Hidefumi Kinoshita

{"title":"一例神经内分泌癌-acinar腺癌混合瘤：前列腺癌三联疗法的应用。","authors":"Junichi Ikeda, Hisanori Taniguchi, Hiroki Takayama, Yuki Masuo, Takahiro Nakamoto, Katsunori Uchida, Hidefumi Kinoshita","doi":"10.1002/iju5.12778","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Neuroendocrine prostate cancer is an aggressive histological subtype of prostate cancer with a poor prognosis. Neuroendocrine prostate cancer is traditionally treated with cisplatin-based chemotherapy, similar to that used in treating small-cell lung cancer. However, the therapeutic effectiveness of chemotherapy for neuroendocrine prostate cancer has been limited. This case report describes a response to triplet therapy using darolutamide, androgen deprivation therapy, and docetaxel, which was administered in a patient with mixed neuroendocrine prostate cancer.</p>\n </section>\n \n <section>\n \n <h3> Case presentation</h3>\n \n <p>A 77-year-old man was newly diagnosed with mixed neuroendocrine prostate cancer. Serum prostate-specific antigen, neuron-specific enolase, and progastrin-releasing peptide levels were 62.2, 40.6, and 60.6 pg/mL, respectively. Multiple lymph node metastases were identified on a computed tomography scan, and bone scintigraphy revealed multiple bone metastases. The clinical stage was determined to be cT3bN1M1b. Ultimately, tumor size and serum markers decreased with triplet therapy.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>We demonstrated the first case in which triplet therapy had been effective in the treatment of neuroendocrine prostate cancer.</p>\n </section>\n </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"7 6","pages":"459-462"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531889/pdf/","citationCount":"0","resultStr":"{\"title\":\"A case of mixed neuroendocrine carcinoma–acinar adenocarcinoma: Utilization of triplet therapy for prostate cancer\",\"authors\":\"Junichi Ikeda, Hisanori Taniguchi, Hiroki Takayama, Yuki Masuo, Takahiro Nakamoto, Katsunori Uchida, Hidefumi Kinoshita\",\"doi\":\"10.1002/iju5.12778\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>Neuroendocrine prostate cancer is an aggressive histological subtype of prostate cancer with a poor prognosis. Neuroendocrine prostate cancer is traditionally treated with cisplatin-based chemotherapy, similar to that used in treating small-cell lung cancer. However, the therapeutic effectiveness of chemotherapy for neuroendocrine prostate cancer has been limited. This case report describes a response to triplet therapy using darolutamide, androgen deprivation therapy, and docetaxel, which was administered in a patient with mixed neuroendocrine prostate cancer.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Case presentation</h3>\\n \\n <p>A 77-year-old man was newly diagnosed with mixed neuroendocrine prostate cancer. Serum prostate-specific antigen, neuron-specific enolase, and progastrin-releasing peptide levels were 62.2, 40.6, and 60.6 pg/mL, respectively. Multiple lymph node metastases were identified on a computed tomography scan, and bone scintigraphy revealed multiple bone metastases. The clinical stage was determined to be cT3bN1M1b. Ultimately, tumor size and serum markers decreased with triplet therapy.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>We demonstrated the first case in which triplet therapy had been effective in the treatment of neuroendocrine prostate cancer.</p>\\n </section>\\n </div>\",\"PeriodicalId\":52909,\"journal\":{\"name\":\"IJU Case Reports\",\"volume\":\"7 6\",\"pages\":\"459-462\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531889/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"IJU Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/iju5.12778\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJU Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iju5.12778","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

简介神经内分泌性前列腺癌是前列腺癌的一种侵袭性组织学亚型，预后较差。神经内分泌前列腺癌传统上采用顺铂化疗，与治疗小细胞肺癌的方法类似。然而，化疗对神经内分泌性前列腺癌的疗效有限。本病例报告描述了一名混合型神经内分泌前列腺癌患者对达罗他胺、雄激素剥夺疗法和多西他赛三联疗法的反应：一名 77 岁的男性新近被诊断出患有混合型神经内分泌前列腺癌。血清前列腺特异性抗原、神经元特异性烯醇化酶和胃泌素释放肽水平分别为 62.2、40.6 和 60.6 pg/mL。计算机断层扫描发现多处淋巴结转移，骨闪烁扫描发现多处骨转移。临床分期被确定为 cT3bN1M1b。最终，肿瘤大小和血清标志物在三联疗法后均有所下降：我们展示了首例三联疗法有效治疗神经内分泌前列腺癌的病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

A case of mixed neuroendocrine carcinoma–acinar adenocarcinoma: Utilization of triplet therapy for prostate cancer

Introduction

Neuroendocrine prostate cancer is an aggressive histological subtype of prostate cancer with a poor prognosis. Neuroendocrine prostate cancer is traditionally treated with cisplatin-based chemotherapy, similar to that used in treating small-cell lung cancer. However, the therapeutic effectiveness of chemotherapy for neuroendocrine prostate cancer has been limited. This case report describes a response to triplet therapy using darolutamide, androgen deprivation therapy, and docetaxel, which was administered in a patient with mixed neuroendocrine prostate cancer.

Case presentation

A 77-year-old man was newly diagnosed with mixed neuroendocrine prostate cancer. Serum prostate-specific antigen, neuron-specific enolase, and progastrin-releasing peptide levels were 62.2, 40.6, and 60.6 pg/mL, respectively. Multiple lymph node metastases were identified on a computed tomography scan, and bone scintigraphy revealed multiple bone metastases. The clinical stage was determined to be cT3bN1M1b. Ultimately, tumor size and serum markers decreased with triplet therapy.